CClinicalTrials.gg
Not yet recruitingNCT07114354PDCogniCareUpdated Aug 11, 2025

Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Disease

An interventional study of PDCogniCare platform in Dementia (Diagnosis), Parkinson Disease Dementia (PDD) and Parkinson Disease (PD), sponsored by The University of Queensland. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by The University of Queensland · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
275
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Dementia is observed in 80% of people living with advanced stage Parkinson's disease, however, there are inadequate opportunities for early and effective diagnosis of dementia in current clinical practice. This study aims to identify whether a new tool called PDCogniCare, can improve detection of dementia in people living with Parkinson's disease, and to explore what factors might influence its use in healthcare services.

Read the detailed description

The PDCogniCare tool integrates best practice guidelines for cognitive evaluations in people living with Parkinson's disease, along with a tailored digital platform to support guideline implementation and routinely track cognitive changes throughout the disease course. We hypothesize that PDCogniCare will significantly enhance cognitive evaluations within healthcare services. Embedded process and economics evaluations will inform implementation and sustainable business models of PDCogniCare.

02

Conditions studied

  • Dementia (Diagnosis)
  • Parkinson Disease Dementia (PDD)
  • Parkinson Disease (PD)

Keywords

  • Parkinson's disease
  • Dementia
  • Cognitive evaluation
  • Implementation
03

In context

Dementia

2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.

This study's planned enrollment of 275 is above the median of 83 across 1,629 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

The University of Queensland is the lead sponsor of 89 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • People living with idiopathic Parkinson's disease, one year or more post-diagnosis, attending Movement Disorder Clinics

Exclusion criteria

Exclusion Criteria:

  • People with severe Parkinson's disease who aren't able to communicate
  • People with comorbid neurological conditions (e.g. Stroke)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
275 participants (estimated)

Study arms

  • Other
    PDCogniCare

    All eligible people living with Parkinson's disease who consent to participate will be registered into the PDCogniCare platform.

    Other: PDCogniCare platform

Interventions

  • OtherPDCogniCare platform

    Digital platform designed to support early and accurate detection of dementia in people living with Parkinson's disease

06

What researchers measure

Primary outcomes

  1. Change in percentage of people with Parkinson's disease diagnosed with dementia

    Time frame: 12 months from enrolment

Secondary outcomes

  1. Change in percentage of people with Parkinson's disease diagnosed with mild cognitive impairment

    Time frame: 12 months from enrolment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pourzinal D, King J, Sivakumaran K, Yang J, McCann E, Mitchell LK, Brooks D, Lehn A, Liddle J, Pachana NA, Tinson H, Shrubsole K, Bailey DX, Dissanayaka NN. Evaluating evidence for a neuropsychological toolkit to predict cognitive decline in PD: A systematic review. Clin Neuropsychol. 2025 Jun 4:1-28. doi: 10.1080/13854046.2025.2511966. Online ahead of print. PubMed 40464273 ↗
  • Pourzinal D, Elgey C, Bailey DX, Yang J, Lehn A, Tinson H, Liddle J, Brooks D, Naismith SL, Shrubsole K, Marsh R, Mitchell LK, Pachana NA, King J, Dissanayaka NN. Diagnosis, evaluation & management of cognitive disorders in Parkinson's disease: A systematic review. Int Psychogeriatr. 2025 May 12:100081. doi: 10.1016/j.inpsyc.2025.100081. Online ahead of print. PubMed 40360335 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07114354
Lead sponsor
The University of Queensland
Collaborators
Medical Research Future Fund, Metro South Health, Metro North Health, Queensland University of Technology, University of Sydney, OPN365, Australian Dementia Network, Dementia Australia, Lions Club of Brisbane Inner North, Parkinson's Queensland
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Aug 18, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 11, 2025

Study contacts

Nadeeka Dissanayaka
Contact
pdcognicare@uq.edu.au
+617 3346 5577
Tiffany Au
Contact
dnmh@uq.edu.au

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion